|
Childhood Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma.
|
30140037 |
2019 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30 is expressed on a variety of B-cell lymphomas, such as Hodgkin lymphoma, primary effusion lymphoma, and a diffuse large B-cell lymphoma subgroup.
|
30962205 |
2019 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL.
|
31616638 |
2019 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hodgkin's lymphoma (HL) has a unique immunophenotype derived from immunohistochemistry (positive for CD15, CD30, and Pax-5; negative for CD3, CD20 in most cases, and CD45).
|
30350336 |
2019 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following a wedge resection, histopathological examination showed Reed-Sternberg cells that were positive for CD-15 and CD-30, which is typical of HL.
|
29742695 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
|
29390984 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Their specific features and relationship to CD30-expressing Hodgkin and Reed/Sternberg (HRS) cells of Hodgkin lymphoma are unclear but highly relevant, because numerous patients with lymphoma are currently treated with an anti-CD30 immunotoxin.
|
29889102 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is an anti-CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30-positive lymphomas, such as Hodgkin lymphoma and ALCL.
|
29806104 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL).
|
29316337 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is a Food and Drug Administration approved anti-CD30 antibody drug conjugate potently active in Hodgkin lymphoma.
|
29280762 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context.234 CD30+ HL patients were enrolled.
|
29207679 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).
|
28427526 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: Anti-CD30 antibody brentuximab vedotin and immune checkpoint inhibitors have shown promising results in patients with relapsed and refractory HL.
|
28359170 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent years, the CD30-directed antibody-drug conjugate brentuximab vedotin (BV) and anti-PD-1 antibodies, nivolumab and pembrolizumab, underwent extensive evaluation in HL.
|
28665214 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain.
|
28805662 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor T cells directed against CD30 have been investigated with preliminary clinical trials showing minimal toxicities and some responses in heavily pre-treated patients with HL.
|
28780614 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
|
28190142 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently an antibody drug conjugate, brentuximab-vedotin (BV), directed against CD30 antigen has shown promise in CD30 expressing hematologic malignancies such as Hodgkin's lymphoma and ALCL.
|
26809026 |
2016 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin was approved in the European Union for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
|
26621039 |
2016 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients had histologically documented CD30+ Hodgkin lymphoma; 74% had refractory disease or early relapses.
|
26768687 |
2016 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MVs from patients specifically expressed tumor-related antigens, such as CD19 in B cell neoplasms, CD38 in MM, CD13 in myeloid tumors, and CD30 in HL.
|
26156801 |
2015 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 2011, the ADC brentuximab-vedotin, consisting of the CD30-specific chimeric mAb cAC10 and the potent tubulin toxin monomethyl auristatin E, gained regulatory approval as a well tolerated and highly active drug in patients with refractory and relapsed HL and ALCL.
|
24043362 |
2014 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clonality detection rates in cHL improved as CD30-positive Reed-Sternberg (RS) cell density increased and CD20-positive B cell density decreased, although these correlations did not reach statistical significance.
|
22296097 |
2012 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ets-1, constitutively activated by ERK1/2-MAPK, plays a central role in the overexpression of JunB and CD30, which are both involved in the pathogenesis of HL and ALCL.
|
22107829 |
2012 |
|
Childhood Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.
|
21619423 |
2011 |